[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100357600":3},{"organization":4,"outcomesModule":7,"designInfo":22,"detailedDescription":29,"studyPopulation":21,"armGroups":30,"interventions":37,"overallOfficials":43,"centralContacts":48,"locations":58,"responsibleParty":366,"collaborators":21,"id":368,"slug":21,"hasResults":369,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":21,"eligibilityCriteria":373,"healthyVolunteers":369,"sex":374,"minAge":375,"maxAge":21,"enrollmentInfo":376,"targetDuration":21,"studyType":379,"phases":380,"briefSummary":382,"conditions":383,"keywords":21,"overallStatus":61,"whyStopped":21,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":394},{"fullName":5,"class":6},"Xynomic Pharmaceuticals, Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":21},[9],{"measure":10,"description":11,"timeFrame":12},"Clinical effect by evaluating the objective response rate (ORR)","To evaluate the objective response rate (ORR) of abexinostat in patients with relapsed\u002Frefractory diffuse large B-cell lymphoma (DLBCL) as assessed by an independent central imaging review.","up to 56 days",[14,17],{"measure":15,"description":16,"timeFrame":12},"Objective Response","Objective response rate (ORR) as assessed by the investigator",{"measure":18,"description":19,"timeFrame":20},"Progression-free survival","Progression-free survival (PFS), defined as the time from the initiation of treatment to disease progression or death as assessed by the independent Central Imaging Review and the Investigator.","Up to 2 years",null,{"allocation":23,"interventionModel":24,"interventionModelDescription":25,"primaryPurpose":26,"observationalModel":21,"timePerspective":21,"maskingInfo":27},"NA","SINGLE_GROUP","A single arm treatment group","TREATMENT",{"masking":28,"maskingDescription":21,"whoMasked":21},"NONE","An open-label, single-arm, multi-center phase 2 study to evaluate the efficacy and safety of oral histone deacetylase (HDAC)-inhibitor abexinostat, as monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)",[31],{"label":32,"type":33,"description":34,"interventionNames":35},"Abexinostat 80 mg bis in die (BID)","EXPERIMENTAL","Abexinostat 80 mg BID",[36],"Drug: abexinostat",[38],{"type":39,"name":40,"description":41,"armGroupLabels":42,"otherNames":21},"DRUG","abexinostat","abexinostat tablet",[32],[44],{"name":45,"affiliation":46,"role":47},"Yuankai SHI, Prof","Cancer Institute and Hospital, Chinese Academy of Medical Sciences","PRINCIPAL_INVESTIGATOR",[49,54],{"name":50,"role":51,"phone":52,"phoneExt":21,"email":53},"Bing Zhao, MD","CONTACT","(01186)13716386801","bing.zhao@xynomicpharma.com",{"name":55,"role":51,"phone":56,"phoneExt":21,"email":57},"Sophia Paspal, PhD RAC","610-405-5974","sophia.paspal@xynomicpharma.com",[59,77,88,99,113,127,141,152,166,177,191,205,219,233,247,261,272,285,299,313,327,341,355],{"facility":60,"status":61,"city":62,"state":21,"zip":63,"country":64,"countryCode":65,"cosmosGeoPoint":66,"geoPoint":71,"contacts":72},"Cancer Hospital Chinese Academy of Medical Sciences","RECRUITING","Beijing","100021","China","CN",{"type":67,"coordinates":68},"Point",[69,70],116.39723,39.9075,{"lat":70,"lon":69},[73],{"name":74,"role":51,"phone":75,"phoneExt":21,"email":76},"Yuankai Shi, MD, PhD","13701251865","syuankaipumc@126.com",{"facility":78,"status":61,"city":62,"state":21,"zip":79,"country":64,"countryCode":65,"cosmosGeoPoint":80,"geoPoint":82,"contacts":83},"China-Japan Friendship Hospital","100029",{"type":67,"coordinates":81},[69,70],{"lat":70,"lon":69},[84],{"name":85,"role":51,"phone":86,"phoneExt":21,"email":87},"Zhenling Li, M.M.","13520114408","zryyxy2013@163.com",{"facility":89,"status":61,"city":62,"state":21,"zip":90,"country":64,"countryCode":65,"cosmosGeoPoint":91,"geoPoint":93,"contacts":94},"Peking University Third Hospital","100191",{"type":67,"coordinates":92},[69,70],{"lat":70,"lon":69},[95],{"name":96,"role":51,"phone":97,"phoneExt":21,"email":98},"Xiaoyan Ke, MD","13911068649","xiaoyank@yahoo.com",{"facility":100,"status":61,"city":101,"state":21,"zip":102,"country":64,"countryCode":65,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"West China Hospital, Sichuan University","Chengdu","610041",{"type":67,"coordinates":104},[105,106],104.06667,30.66667,{"lat":106,"lon":105},[109],{"name":110,"role":51,"phone":111,"phoneExt":21,"email":112},"Liqun Zou, MD","18980601027","zliqun@hotmail.com",{"facility":114,"status":61,"city":115,"state":21,"zip":116,"country":64,"countryCode":65,"cosmosGeoPoint":117,"geoPoint":121,"contacts":122},"The First Affiliate Hospital of Dalian Medical University","Dalian","116011",{"type":67,"coordinates":118},[119,120],121.60222,38.91222,{"lat":120,"lon":119},[123],{"name":124,"role":51,"phone":125,"phoneExt":21,"email":126},"Yajie Gao, M.M.","15541192088","gaoyajie100@126.com",{"facility":128,"status":61,"city":129,"state":21,"zip":130,"country":64,"countryCode":65,"cosmosGeoPoint":131,"geoPoint":135,"contacts":136},"Fujian Medical University Union Hospital","Fuzhou","350001",{"type":67,"coordinates":132},[133,134],119.30611,26.06139,{"lat":134,"lon":133},[137],{"name":138,"role":51,"phone":139,"phoneExt":21,"email":140},"Tingbo Liu, PhD","13365910316","13769988835@139.com",{"facility":142,"status":61,"city":129,"state":21,"zip":143,"country":64,"countryCode":65,"cosmosGeoPoint":144,"geoPoint":146,"contacts":147},"Fujian Provincial Cancer Hospital","350014",{"type":67,"coordinates":145},[133,134],{"lat":134,"lon":133},[148],{"name":149,"role":51,"phone":150,"phoneExt":21,"email":151},"Hui Wu, M.M.","13509320201","kkwff123@163.com",{"facility":153,"status":61,"city":154,"state":21,"zip":155,"country":64,"countryCode":65,"cosmosGeoPoint":156,"geoPoint":160,"contacts":161},"Cancer Center of Guangzhou Medical University","Guangzhou","510030",{"type":67,"coordinates":157},[158,159],113.25,23.11667,{"lat":159,"lon":158},[162],{"name":163,"role":51,"phone":164,"phoneExt":21,"email":165},"Chuan Jin, M.M.","13688896983","jinchuan5959@163.com",{"facility":167,"status":61,"city":154,"state":21,"zip":168,"country":64,"countryCode":65,"cosmosGeoPoint":169,"geoPoint":171,"contacts":172},"Sun Yai-Sen Memorial Hospital, Sun Yai-Sen University","510120",{"type":67,"coordinates":170},[158,159],{"lat":159,"lon":158},[173],{"name":174,"role":51,"phone":175,"phoneExt":21,"email":176},"Yudan Wu, M.M.","13719472080","danwuxu@126.com",{"facility":178,"status":61,"city":179,"state":21,"zip":180,"country":64,"countryCode":65,"cosmosGeoPoint":181,"geoPoint":185,"contacts":186},"Zhejiang Cancer Hospital","Hangzhou","310022",{"type":67,"coordinates":182},[183,184],120.16142,30.29365,{"lat":184,"lon":183},[187],{"name":188,"role":51,"phone":189,"phoneExt":21,"email":190},"Haiyan Yang, MD","13857182590","haiyanyang1125@163.com",{"facility":192,"status":61,"city":193,"state":21,"zip":194,"country":64,"countryCode":65,"cosmosGeoPoint":195,"geoPoint":199,"contacts":200},"The Affiliated Tumor Hospital of Harbin Medical University","Harbin","150081",{"type":67,"coordinates":196},[197,198],126.65,45.75,{"lat":198,"lon":197},[201],{"name":202,"role":51,"phone":203,"phoneExt":21,"email":204},"Qingyuan Zhang, MD","13313612989","sy86298276@163.com",{"facility":206,"status":61,"city":207,"state":21,"zip":208,"country":64,"countryCode":65,"cosmosGeoPoint":209,"geoPoint":213,"contacts":214},"The First Hospital of Lanzhou University","Lanzhou","730000",{"type":67,"coordinates":210},[211,212],103.83987,36.05701,{"lat":212,"lon":211},[215],{"name":216,"role":51,"phone":217,"phoneExt":21,"email":218},"Yaming Xi, MD","13919110815","xiyaming02@163.com",{"facility":220,"status":61,"city":221,"state":21,"zip":222,"country":64,"countryCode":65,"cosmosGeoPoint":223,"geoPoint":227,"contacts":228},"Linyi Cancer Hospital","Linyi","276000",{"type":67,"coordinates":224},[225,226],118.34278,35.06306,{"lat":226,"lon":225},[229],{"name":230,"role":51,"phone":231,"phoneExt":21,"email":232},"Zhen Wang, M.M.","15168920632","LYSZLYYNSK@163.com",{"facility":234,"status":61,"city":235,"state":21,"zip":236,"country":64,"countryCode":65,"cosmosGeoPoint":237,"geoPoint":241,"contacts":242},"Nantong Tumor Hospital","Nantong","226361",{"type":67,"coordinates":238},[239,240],120.87472,32.03028,{"lat":240,"lon":239},[243],{"name":244,"role":51,"phone":245,"phoneExt":21,"email":246},"Xiaohong Xu, MD","18912296003","xhx107@163.com",{"facility":248,"status":61,"city":249,"state":21,"zip":250,"country":64,"countryCode":65,"cosmosGeoPoint":251,"geoPoint":255,"contacts":256},"Shanghai Jiao Tong University School Medicine","Shanghai","200025",{"type":67,"coordinates":252},[253,254],121.45806,31.22222,{"lat":254,"lon":253},[257],{"name":258,"role":51,"phone":259,"phoneExt":21,"email":260},"Chunkang Chang, MD","13764643870","Changchunkang7010@126.com",{"facility":262,"status":61,"city":249,"state":21,"zip":263,"country":64,"countryCode":65,"cosmosGeoPoint":264,"geoPoint":266,"contacts":267},"Fudan University Shanghai Cancer Center","200032",{"type":67,"coordinates":265},[253,254],{"lat":254,"lon":253},[268],{"name":269,"role":51,"phone":270,"phoneExt":21,"email":271},"Junning Cao, M.M.","13817384270","cao_junning@126.com",{"facility":273,"status":61,"city":274,"state":21,"zip":64,"country":64,"countryCode":65,"cosmosGeoPoint":275,"geoPoint":279,"contacts":280},"Second People's Hospital of Shenzhen","Shenzhen",{"type":67,"coordinates":276},[277,278],114.0683,22.54554,{"lat":278,"lon":277},[281],{"name":282,"role":51,"phone":283,"phoneExt":21,"email":284},"Xin Du, MD","13602523722","duxingz@medmail.com.cn",{"facility":286,"status":61,"city":287,"state":21,"zip":288,"country":64,"countryCode":65,"cosmosGeoPoint":289,"geoPoint":293,"contacts":294},"The Forth Hospital of Hebei Medical University","Shijiazhuang","050011",{"type":67,"coordinates":290},[291,292],114.47861,38.04139,{"lat":292,"lon":291},[295],{"name":296,"role":51,"phone":297,"phoneExt":21,"email":298},"Yuhuan Gao, MD","13503217908","ydsygao@sina.com",{"facility":300,"status":61,"city":301,"state":21,"zip":302,"country":64,"countryCode":65,"cosmosGeoPoint":303,"geoPoint":307,"contacts":308},"First Hospital of Shanxi Medical University","Taiyuan","030001",{"type":67,"coordinates":304},[305,306],112.56028,37.86944,{"lat":306,"lon":305},[309],{"name":310,"role":51,"phone":311,"phoneExt":21,"email":312},"Weihua Zhang, MD","13015474570","zwhlzh@126.com",{"facility":314,"status":61,"city":315,"state":21,"zip":316,"country":64,"countryCode":65,"cosmosGeoPoint":317,"geoPoint":321,"contacts":322},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Wuhan","430000",{"type":67,"coordinates":318},[319,320],114.26667,30.58333,{"lat":320,"lon":319},[323],{"name":324,"role":51,"phone":325,"phoneExt":21,"email":326},"Liling Zhang, MD","15871725926","lily1228@sina.com",{"facility":328,"status":61,"city":329,"state":21,"zip":330,"country":64,"countryCode":65,"cosmosGeoPoint":331,"geoPoint":335,"contacts":336},"The Affiliated Hospital of Xuzhou Medical University","Xuzhou","221006",{"type":67,"coordinates":332},[333,334],117.28386,34.20442,{"lat":334,"lon":333},[337],{"name":338,"role":51,"phone":339,"phoneExt":21,"email":340},"Zhenyu Li, MD","13852439312","frankfeng_2004@126.com",{"facility":342,"status":61,"city":343,"state":21,"zip":344,"country":64,"countryCode":65,"cosmosGeoPoint":345,"geoPoint":349,"contacts":350},"Henan Cancer Hospital","Zhengzhou","450008",{"type":67,"coordinates":346},[347,348],113.64861,34.75778,{"lat":348,"lon":347},[351],{"name":352,"role":51,"phone":353,"phoneExt":21,"email":354},"Yufu Li, MD","13598009218","liyufu439@163.com",{"facility":356,"status":61,"city":343,"state":21,"zip":357,"country":64,"countryCode":65,"cosmosGeoPoint":358,"geoPoint":360,"contacts":361},"The First Affiliated Hospital of Zhengzhou University","450052",{"type":67,"coordinates":359},[347,348],{"lat":348,"lon":347},[362],{"name":363,"role":51,"phone":364,"phoneExt":21,"email":365},"Mingzhi Zhang, MD","13838565629","mingzhi_zhang@163.com",{"type":367,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100357600",false,"NCT03936153","Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)","An Open-label, Single-arm, Multi-center Phase 2 Study to Evaluate the Efficacy and Safety of Abexinostat as Monotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)","Inclusion Criteria:\n\n1. Histologically confirmed diffuse large B-cell lymphoma (DLBCL);\n2. Have received only two prior standard therapy lines for diffuse large B-cell lymphoma (DLBCL) including anti- cluster of differentiation antigen (anti-CD20) antibody and cytotoxic therapy;\n3. Confirmed to be unresponsive to the last line of therapy, or have disease progression following the last line of therapy;\n4. Have at least one radiologically measurable lymph node or extranodal lymphoid malignant lesion;\n5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2;\n6. Meet various hematological, liver and renal function lab parameters.\n\nExclusion Criteria:\n\n1. Have primary central nervous system (CNS) lymphoma or secondary central nervous system (CNS) infiltration, transformed lymphoma, unclassified B-cell lymphoma with features intermediate between DLBCL and classical Hodgkin's lymphoma (HL), primary effusion lymphoma, plasma lymphoma;\n2. Toxicity not yet recovered from previous anti-tumor therapies;\n3. Uncontrolled systemic infections or infections requiring intravenous antibiotics;\n4. Have received steroid hormone, chemotherapy, targeted therapy, radiotherapy, antibody-based therapies, within a specified amount of time per protocol;\n5. Unable to swallow tablets, or presence of significant functional gastrointestinal disorders that may affect the intake, transport or absorption of the study drug;\n6. Have received autologous stem cell transplant,or allogeneic stem cell transplant within a certain amount of time as specified in protocol;\n7. Presence of active graft-versus-host reaction;\n8. Have undergone a major surgery within the last month;\n9. Evidence of possible human immunodeficiency virus (HIV) infection or hepatitis C virus (HCV) infection;\n10. Have any cardiac impairment as defined per protocol;\n11. Have prior history of malignancies other than diffuse large B-cell lymphoma (DLBCL).","ALL","18 Years",{"count":377,"type":378},170,"ESTIMATED","INTERVENTIONAL",[381],"PHASE2","An open-label, single-arm, multi-center phase 2 study to evaluate the efficacy and safety of abexinostat, as monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)",[384],"Diffuse Large B-cell Lymphoma (DLBCL)","2025-04-09",{"date":387,"type":388},"2025-04-10","ACTUAL",{"date":390,"type":388},"2020-01-20",{"date":392,"type":378},"2027-08-31",{"name":5,"class":6},23]